Ciclosporin For Severe Refractory Colitis

##plugins.themes.academic_pro.article.sidebar##

Published May 20, 2010
Download
pdf
Vol. 88 No. 6 (2010): Issue Jun 2010

##plugins.themes.academic_pro.article.main##

Asma Ouakaa-Kchaou
Service de Gastro-entérologie Hôpital H. Thameur Tunis
Dalila Gargouri
Service de Gastro-entérologie Hôpital H. Thameur Tunis
Hela Elloumi
Jamel Kharrat
Abdeljabbar Ghorbel

Abstract

Background : Intravenous ciclosporin is a promising alternative, rapidly effective, for patients with severe steroid-refractory colitis previously facing only surgical options, however its use is controversial because of the frequency of adverse effects and the doubt about the long-term response.
Aim: This review will provide information on clinical pharmacology, clinical indications for use, methods of dose adjustment, monitoring of metabolites for efficacy and for potential side effects and the adverse event profile of ciclosporin in severe refractory colitis.
Methods: Literature review
Results: Toxicity is dominated by opportunistic infections. Renal and neurotoxicity are also recognized. Risks of toxicity can be reduced by using lower doses, by oral microemulsion or by monotherapy without corticosteroids. The drug should not be continued for more than 3 to 6 months. As a bridge to other maintenance therapy such as azathioprine or 6-mercaptopurine ciclosporin can be an effective treatment.
Conclusion : CSA is a viable alternative to emergency colectomy in severe UC in the short term. Although these benefits are not maintained in all patients, more than a half will also avoid colectomy in the longer term. Careful selection and monitoring of patients, use of lower doses, and oral therapy will help to reduce side effects.

Keywords:

refractory colitis, ciclosporin

##plugins.themes.academic_pro.article.details##

References

  1. Barney Hawthorne A. Ciclosporin and refractory colitis. Eur J Gastroenterol Hepatol 2003; 15:239-44.
  2. Siegel CA, Sands BE. Practical management of inflammatory bowel disease patients taking immunomodulators. Aliment Pharmacol Ther 2005;22:1-16.
  3. Aberra FN, Lichtenstein GR. Monitoring of immunomodulators in inflammatory bowel disease. Aliment Pharmacol Ther 2005;21:307-19.
  4. Sandborn WJ. A critical review of cyclosporin therapy in inflammatory bowel disease. Inflam Bowel Dis 1995;1:48-63.
  5. Actis GC, Ottobrelli A, Pera A et al. Continuously infused cyclosporine at low dose is sufficient to avoid emergency colectomy in acute attacks of ulcerative colitis without the need for high-dose steroids. J Clin Gastroenterol 1993;17:10-3.
  6. Lichtiger S, Present DH, Kornbluth A. et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Eng J Med 1994;330:1841-5.
  7. Van Assche G, Vermeire S, Rutgeerts P. Treatment of severe steroid refractory ulcerative colitis. World J Gastroenterol. 2008;14:5508-11.
  8. De Saussure P, Soravia C, Morel P, Hadengue A. Low-dose oral microemulsion ciclosporin for severe, refractory ulcerative colitis. Aliment Pharmacol Ther 2005;22:203-8.
  9. Weber A, Fein F, Koch S, Dupont-Gossart AC, Mantion G, Heyd B, Carbonnel F. Treatment of ulcerative colitis refractory to steroid therapy by oral microemulsion cyclosporine. Inflam Bowel Dis 2006;12:1131-5.
  10. Rayner CK, McCormack G, Emmanuel V, Kamm MA. Long-term results of low-dose intravenous ciclosporin for acute severe ulcerative colitis. Aliment Pharmacol Ther 2003;182:303-8.
  11. Travis SPL, Stange EF, Lémann M, Oresland T, Bemelman WA, Chowers Y, Colombel JF, D'Haens G, Ghosh S, Marteau P, Kruis W, Mortensen NJ, Penninckx F, Gassull M for the European Crohn's and Colitis Organisation (ECCO). European evidencebased Consensus on the management of ulcerative colitis: Current management. J Crohn Colitis 2008;2: 24-62.
  12. Sandborn WJ, Tremaine WJ, Schroeder KW, Batts KP, Lawson GM, Steiner BL, et al. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology 1994;106:1429-35.
  13. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporine in ulcerative colitis: a five-year experience. Am J Gastroenterol. 1999;94:1587-92.
  14. Message L, Bourreille A, Laharie D, Quinton A, Galmiche JP, Lamouliatte H, Alamdari A, Zerbib F. Efficacy of intravenous cyclosporin in moderately severe ulcerative colitis refractory to steroids. Gastroenterol Clin Biol 2005;29:231-5.
  15. Stack WA, Long RG, Hawkey CJ. Short and long-term outcome of patients treated with cyclosporine for severe acute ulcerative colitis. Aliment Pharmacol Ther 1998;12:973-8.
  16. Campbell S, Travis S, Jewell D. Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur J Gastroenterol Hepatol 2005;17:79-84.